Banner
Identification
Name Secretin
Accession Number DB00021 (BIOD00039, BTD00039)
Type biotech
Groups approved
Description

This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine’s contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered.
Protein structure Db00021
Display: 3D Structure
Protein chemical formula C130H219N43O42
Protein average weight 3056.4000
Sequences 
>DB00021 sequence
HSDGTFTSELSRLRDSARLQRLLQGLV

FASTA
Synonyms
Secremax, SecreFlo
Salts Not Available
Brand names
Name Company
SecreFlo
Secremax, SecreFlo (Repligen Corp)
Brand mixtures Not Available
Categories
  • Diagnostic Agents
CAS number Not Available
Taxonomy
Kingdom Not Available
Classes Not Available
Substructures Not Available
Pharmacology
Indication For diagnosis of pancreatic exocrine dysfunction and gastrinoma
Pharmacodynamics Used in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach.
Mechanism of action Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone
Absorption Not Available
Volume of distribution Not Available
Protein binding Not Available
Metabolism
Not Available
Route of elimination Not Available
Half life Not Available
Clearance Not Available
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Pathways Not Available
Pharmacoeconomics
Manufacturers
  • Ferring pharmaceuticals inc
  • Chirhoclin inc
Packagers
  • Professional Co.
Dosage forms
Form Route Strength
Injection, powder, lyophilized, for solution Intravenous
Prices
Unit description Cost Unit
Secretin-mannitol powder 1.43 USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents Not Available
Properties
State solid
Experimental Properties
Property Value Source
hydrophobicity -0.463 Not Available
isoelectric point 9.45 Not Available
References
Synthesis Reference Not Available
General Reference Not Available
External Links
Resource Link
PharmGKB PA164760844 Link_out
Drug Product Database 874000 Link_out
RxList http://www.rxlist.com/cgi/generic3/secretin.htm Link_out
Drugs.com http://www.drugs.com/human_secretin.html Link_out
Wikipedia http://en.wikipedia.org/wiki/Secretin Link_out
ATC Codes
  • V04CK01
AHFS Codes Not Available
PDB Entries
FDA label Not Available
MSDS Not Available
Interactions
Drug Interactions
Drug Interaction
Clidinium Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely.
Tiotropium The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Tolterodine The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Trihexyphenidyl The stimulatory effect of Secretin may be reduced by anticholinergics such as Trihexyphenidyl. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Trimethobenzamide The stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Trospium The stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Food Interactions Not Available
Targets

1. Secretin receptor

Pharmacological action: yes
Actions: agonist

This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase

Organism class: human
UniProt ID: P47872 Link_out
Gene: SCTR Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
Comments
Drug created on June 13, 2005 07:24 / Updated on June 14, 2012 11:21